Worawan Bunrasmee

Worawan Bunrasmee

Auto-generated profile, based on publicly available information

Worawan Bunrasmee

Chulalongkorn University 3 Center of Excellence in Immunology and Immune-Mediated Diseases, Faculty of Medicine Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Purpose: To evaluate the safety and immunogenicity of intramuscularly delivered personalized neoantigen synthetic long peptide (SLP) vaccines in patients with advanced solid tumors. Patients and Methods: In this phase I trial, 12 patients with advanced melanoma (n = 9) or renal cell carcinoma (n = 3) who lacked access to further reimbursed standard therapies at enrollment received intramuscular neoantigen SLP vaccines with Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC). Each vaccine contained about 20 predicted neoantigen peptides. Adverse events were monitored throughout vaccination and follow-up. Immune profiling was performed at baseline and predefined postvaccination time points. Results: Intramuscular neoantigen vaccination was well tolerated, with only grade 1 to 2 local pain or fever and no immune-mediated toxicities. All participants developed de novo T-cell responses, which were detectable as early as 1 week after vaccination in most patients. On average, 53% of peptides per patient were immunogenic, inducing both CD8+ and CD4+ neoantigen-specific responses. Patients previously treated with immune checkpoint inhibitors (ICI) had higher baseline immunity but achieved comparable postvaccination responses to ICI-naïve patients. IFNγ-dominant CD8+ and TNFα-dominant CD4+ responses were observed, along with increased effector memory differentiation. Two patients with higher CD8+ terminal effector memory RA (TEMRA) proportions were the longest survivors. Tumor biopsies revealed enhanced CD8+ infiltration, and epitope spreading occurred in two evaluable cases. An analysis of 239 peptides showed greater immunogenicity for dual MHC I/II–binding, cysteine-containing, in-frame insertions or deletions–derived or low variant allele frequency–derived mutations, whereas proline substitutions reduced responses. Conclusions: Intramuscular neoantigen SLP vaccination with poly-ICLC is safe and induces rapid, mutation-specific T-cell immunity with robust CD8+ effector responses. These findings support intramuscular administration as a promising strategy for peptide-based cancer vaccines.

3 August 2026
Verified
Other
Open access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Supplementary Data 2 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma


3 August 2026
Verified
Other
Open access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Purpose:To evaluate the safety and immunogenicity of intramuscularly delivered personalized neoantigen synthetic long peptide (SLP) vaccines in patients with advanced solid tumors. Patients and Methods:In this phase I trial, 12 patients with advanced melanoma (n = 9) or renal cell carcinoma (n = 3) who lacked access to further reimbursed standard therapies at enrollment received intramuscular neoantigen SLP vaccines with Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC). Each vaccine contained about 20 predicted neoantigen peptides. Adverse events were monitored throughout vaccination and follow-up. Immune profiling was performed at baseline and predefined postvaccination time points. Results:Intramuscular neoantigen vaccination was well tolerated, with only grade 1 to 2 local pain or fever and no immune-mediated toxicities. All participants developed de novo T-cell responses, which were detectable as early as 1 week after vaccination in most patients. On average, 53% of peptides per patient were immunogenic, inducing both CD8+ and CD4+ neoantigen-specific responses. Patients previously treated with immune checkpoint inhibitors (ICI) had higher baseline immunity but achieved comparable postvaccination responses to ICI-naïve patients. IFNγ-dominant CD8+ and TNFα-dominant CD4+ responses were observed, along with increased effector memory differentiation. Two patients with higher CD8+ terminal effector memory RA (TEMRA) proportions were the longest survivors. Tumor biopsies revealed enhanced CD8+ infiltration, and epitope spreading occurred in two evaluable cases. An analysis of 239 peptides showed greater immunogenicity for dual MHC I/II–binding, cysteine-containing, in-frame insertions or deletions–derived or low variant allele frequency–derived mutations, whereas proline substitutions reduced responses. Conclusions:Intramuscular neoantigen SLP vaccination with poly-ICLC is safe and induces rapid, mutation-specific T-cell immunity with robust CD8+ effector responses. These findings support intramuscular administration as a promising strategy for peptide-based cancer vaccines.

3 August 2026
Verified
Other
Open access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Supplementary Data 1 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

3 August 2026
Verified
Other
Open access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Supplementary Data 4 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma